

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
2 May 2013 (02.05.2013)



(10) International Publication Number
WO 2013/061205 A8

- (51) International Patent Classification:
C07D 405/06 (2006.01) **A61P 29/00** (2006.01)
A61K 31/417 (2006.01)
- (21) International Application Number:
PCT/IB2012/055610
- (22) International Filing Date:
15 October 2012 (15.10.2012)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/551,628 26 October 2011 (26.10.2011) US
- (71) Applicant: **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich Kent CT13 9NJ (GB).
- (72) Inventors: **BAGAL, Sharanjeet Kaur**; with an address at c/o Neusentis, Portway Building, Granta Park, Great Abington Cambridge CB21 6GP (GB). **KEMP, Mark Ian**; with an address at c/o Pfizer Limited, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **MILLER, Duncan Charles**; with an address at c/o Pfizer Limited, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **MURATA, Yoshi-hisa**; with an address at c/o Pfizer Limited, Ramsgate Road, Sandwich Kent CT13 9NJ (GB).
- (74) Agent: **DROUIN, Stephane**; Pfizer Limited, Ramsgate Road, Sandwich Kent CT13 9NJ (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:


- with international search report (Art. 21(3))

(88) Date of publication of the international search report:
27 June 2013

(48) Date of publication of this corrected version:
27 March 2014

(15) Information about Correction:
see Notice of 27 March 2014

(54) Title: (4-PHENYLMIDAZOL-2-YL) ETHYLAMINE DERIVATIVES USEFUL AS SODIUM CHANNEL MODULATORS



(57) Abstract: The invention relates to imidazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new imidazole Na_v1.8 modulators of formula (I) or a pharmaceutically acceptable salt thereof, wherein R¹, R², R³, R⁴ and R⁵ are as defined in the description. Na_v1.8 modulators are potentially useful in the treatment of a wide range of disorders, particularly pain.